Cerbios supplies Glycopyrronium as a crystalline or micronized powder, for both oral and injectable formulations.

Glycopyrronium bromide is a synthetic anticholinergic drug indicated for the treatment of gastrointestinal disorders like peptic ulcer, to diminish secretions, block cardiac vagal reflexes before surgery and for the long-term treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).

Glycopyrronium is available in different formulations, such as tablets, lyophilized injections and capsules for Dry Powder Inhaler (DPI). Administered to the lungs with a DPI device, Glycopyrronium behaves as a long-acting muscarinic antagonist (LAMA) and is used for maintenance treatment of patients with COPD.

* Products covered by valid patents in any country are not offered or supplied to these countries for commercial purposes. Where valid patents are in place, only use for research and development is allowed, if permitted by the relevant laws.


Glycopyrronium for injection is used before surgery to decrease the volume of secretions of mouth, lungs and stomach. It can also be used either before or during surgery to maintain the heart’s normal beating rhythm.

In Dry Powder Inhalers (DPI) it is used for maintenance treatment in patients with COPD.


CAS Number :
Formula :
Molecular Weight :

398.3 g/mol


China DFM :

Under preparation
Under preparation


  • Long-acting muscarinic antagonist

Therapeutic area

  • Anaesthetic adjuvant
  • Gastrointestinal
  • Anti-asthma and COPD


  • Glycopyrrolate 
  • Pyrrolidinium, 3-[(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethyl-, bromide (1:1) 
  • 3-Hydroxy-1,1-dimethylpyrrolidinium bromide α-cyclopentylmandelate 
  • Pyrrolidinium, 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethyl-, bromide